AMLX

Amylyx Pharmaceuticals INC

+$232.4M

Net Activity

Institutions Holding

173

Popularity Rank

#3244

Avg Weight

0.34%

Total Value

$1.6B

Ownership Trend

173 institutions currently hold AMLX, with 86 net buyers and 89 net sellers this quarter.

Institutional Moves

Institutional Moves (Q1 2026)

Neutral

Based on recent trading activity

Net Selling Institutions

89

Net Buying Institutions

86

Key Holders

View all 173 holding institutions

Quarterly Activity

Recent Activity

+$691.9M

Total Buy Value

$473.8M

Total Sell Value

New buy21
Trim54
Add65
Sold out35

86

Net Buyers

89

Net Sellers

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

1

Filings (90d)

$536K

Total Est. Value

30K shares

Planned Shares

Last Filed 2026-07-09
FilerFiling DateEst. Value
GINA MAZZARIELLO2026-07-09$536K

Form 144 is a planned sale notice, not an executed transaction. Form 144 Tracker

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

FAQ

Who are the top institutional investors holding AMYLYX PHARMACEUTICALS INC (AMLX)?
Major stakeholders currently include FMR LLC ($231.2M), BlackRock, Inc. ($122.7M), Perceptive Advisors LLC ($115.2M). Based on the latest 13F filings, there are a total of 173 tracked investment funds and institutions maintaining positions in AMLX.
What is the overall institutional sentiment toward AMLX recently?
Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $232.4M, driven by 86 managers accumulating shares while 89 reduced their exposure.
Which institutions have been selling or reducing their AMLX positions?
In the latest period, 54 funds trimmed their holdings, and 35 managers completely exited their positions. The aggregate reported sell value was $473.8M.
Are there any notable investors adding AMLX to their portfolios?
Yes, buying activity remains notable. 21 institutions opened new positions in {ticker}, and 65 existing holders added to their shares. The total reported buy value for the quarter amounted to $691.9M.

Related Stocks